SCHEMBL29653512

SCHEMBL29653512

COC(=O)c1cnc(OC)c(Br)c1N1CC[C@H](NC(=O)OC(C)(C)C)C1

nearest known ligand 0.44

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ SUV39H2 Q9H5I1 8/20 0.44
▸ CKS1B P61024 1/20 0.43
▸ SKP1 P63208 1/20 0.43
▸ SKP2 Q13309 1/20 0.43
▸ JAK3 P52333 1/20 0.42
▸ BTK Q06187 1/20 0.42
▸ OPRK1 P41145 3/20 0.41
▸ CTSK P43235 2/20 0.41
▸ PDE10A Q9Y233 2/20 0.41
▸ PIM1 P11309 1/20 0.40
▸ PIM3 Q86V86 1/20 0.40
▸ PIM2 Q9P1W9 1/20 0.40
▸ MAP4K4 O95819 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31243162 1.00 SUV39H2 (0.44) SUV39H2CKS1BSKP1SKP2JAK3
SCHEMBL22976538 0.92 CKS1B (0.45) SUV39H2CKS1BSKP1SKP2JAK3
SCHEMBL22976541 0.92 CKS1B (0.45) SUV39H2CKS1BSKP1SKP2JAK3
SCHEMBL31243179 0.83 SUV39H2 (0.43) SUV39H2CKS1BSKP1SKP2JAK3
SCHEMBL29653468 0.83 SUV39H2 (0.43) SUV39H2CKS1BSKP1SKP2JAK3
SCHEMBL30897173 0.80 CKS1B (0.46) SUV39H2CKS1BSKP1SKP2JAK3
SCHEMBL29653524 0.78 JAK3 (0.47) SUV39H2CKS1BSKP1SKP2JAK3
SCHEMBL28777472 0.78 JAK3 (0.47) SUV39H2CKS1BSKP1SKP2JAK3
SCHEMBL28777474 0.78 JAK3 (0.47) SUV39H2CKS1BSKP1SKP2JAK3
SCHEMBL29653499 0.77 JAK3 (0.52) SUV39H2CKS1BSKP1SKP2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12600709-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2026-04-14 — — US disclosed
US-20250136573-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2025-05-01 — — US disclosed
CN-119504705-A Non-peptide somatostatin 5 receptor agonists and uses thereof 克林提克斯医药股份有限公司 2025-02-25 — — CN disclosed
CN-114585614-B Non-peptide somatostatin 5 receptor agonists and uses thereof 克林提克斯医药股份有限公司 2024-12-03 — — CN disclosed
US-11479540-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2022-10-25 — — US disclosed
EP-4013748-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2022-06-22 — — EP disclosed
US-20220144802-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2022-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144802-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF SSTR5, SSTR4, SSTR3 SUV39H2 3767/4885CKS1B 4459/4885SKP1 4423/4885
US-11479540-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof SSTR5, SSTR4, SSTR3 SUV39H2 3767/4885CKS1B 4459/4885SKP1 4423/4885
US-20250136573-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF SSTR5, SSTR4, SSTR3 SUV39H2 3767/4885CKS1B 4459/4885SKP1 4423/4885
US-12600709-B2 Nonpeptide somatostatin type 5 receptor agonists and uses thereof SSTR5, SSTR4, GLP1R SUV39H2 2740/4885CKS1B 3880/4885SKP1 2814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback